Delmitide acetate (RDP58) is an orally active d-isomer decapeptide with potent anti-inflammatory properties, suppressing TNF-α, IFN-γ, and interleukin (IL)-12 production, while enhancing heme oxygenase 1 activity. It is utilized in research related to ulcerative colitis [1] [2].

Delmitide acetate administered orally at doses of 2.5, 5, and 10 mg/kg daily markedly mitigated CPT-11-induced diarrhea, mucosal inflammation, and mortality in mice by inhibiting the excessive synthesis of proinflammatory cytokines, including TNF-a, IFN-y, and IL-12, in vivo [2]. Furthermore, it fostered an improved tumor response and extended the duration until relapse, all without concurrent gastrointestinal toxicity in the mice [2].